Experimental Bladder Cancer Therapy Cretostimogene Cut Recurrence Risk 68% Versus Surveillance in Company-Reported Phase 3 Trial
CG Oncology reported that cretostimogene reduced bladder cancer recurrence risk by 68% versus surveillance in a 367-patient Phase 3 trial, though full results are pending.
Medical Daily ·